$SLGC News

Last published 2y ago

2y agoSLGCOncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024PR NewswireOncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting...
2y agoLAB SLGCStandard BioTools Stockholders Approve Merger with SomaLogicGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its
2y agoSLGC LABSomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special MeetingPR NewswireSomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided ...
2y agoLAB SLGCMadryn Asset Management Demands SomaLogic's Board Address Repeated, Unprecedented Adjournments of Tainted Special MeetingBusiness WireBelieves All SomaLogic Directors – Robert Barchi, Thomas Carey, Eli Casdin, Troy Cox, Kathy Hibbs, Anne Margulies, Tycho Peterson, Richard Post and Jason Ryan – Have Betrayed Shareholders by Delaying the Special Meeting
2y agoLAB SLGCMadryn Asset Management Addresses SomaLogic's Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioToolsBusiness WireBelieves Two Last-Minute Adjournments of Special Meeting Stem From Fellow Shareholders Recognizing the Deal Consideration Assigns No Value to SomaLogic's Desirable Assets and Represents a Material Discount to Company's
2y agoLAB SLGCProxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioToolsBusiness WireMadryn Asset Management, LP ("Madryn Asset Management" and, collectively with its affiliates, "Madryn"), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. ("SomaLogic" or the "Company")
2y agoSLGCSomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioToolsPR NewswireSomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders urging them...
2y agoLAB SLGCBoston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioToolsBusiness WireBoston Millennia Partners ("Boston Millennia"), a significant shareholder of SomaLogic (the "Company") (NASDAQ:SLGC) today announced that it intends to vote against the Company's planned merger (the "Merger") with
2y agoLAB LH SLGCMadryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional DisclosuresBusiness WireHighlights That Four SomaLogic Shareholders Have Now Openly Stated Their Intention to Vote "AGAINST" the Proposed Merger with Standard BioTools Urges Fellow Shareholders to Vote "AGAINST" the Proposed Merger and Allow
2y agoSLGCLeading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioToolsPR NewswireSomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today announced that Glass Lewis & Co. ("Glass Lewis") has recommended that...
2y agoSLGCSomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All StockholdersPR NewswireSomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating...
2y agoSLGC LABDr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioToolsPR NewswireDr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief...
2y agoSLGC LAB LHSomaLogic Issues Statement Correcting Madryn Asset Management's Misleading DisclosurePR NewswireSomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today issued the following statement in response to a press release issued by...
2y agoLAB LH SLGCMadryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of AlternativesBusiness WireCorrespondence Show SomaLogic Failed to Engage with Labcorp – One of the Industry's Leading Strategics, with a $19 Billion Market Cap – Prior to Pursuing Standard BioTools Deal Madryn Will Continue to Identify Other
2y agoLAB SLGCMadryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw "Cautionary Support" for SomaLogic's Value-Destructive Proposed Merger with Standard BioToolsBusiness WireHighlights Current Merger Consideration, Which Assigns No Value and No Premium to SomaLogic's Desirable Assets, Represents a Material Discount to Company's Cash Reiterates Combined Entity's Proforma Capital Structure
2y agoLAB SLGCTikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioToolsBusiness WireTikvah Management ("Tikvah"), a significant shareholder of Somalogic (the "Company") (NASDAQ:SLGC) with voting rights for 5.9 million shares, or 3.1% of the outstanding shares of Somalogic, today announced that it
2y agoILMN LAB SLGCMadryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioToolsBusiness WirePreliminary Review of ISS Report, Which Recommends "Cautionary Support" for the Proposed Merger, Indicates It Contains Factually Inaccurate Information and Does Not Align with Prior Contested Transaction
2y agoSLGCISS Recommends SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioToolsGlobeNewswireBOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services ("ISS") has recommended that SomaLogic stockholders vote
2y agoLAB SLGCMadryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioToolsBusiness WireLate-Stage Updates to Merger Proxy Spotlight Troubling Connections and Ongoing Business Relationships Among Members of SomaLogic Transaction Committee and Eli Casdin and Casdin Capital Madryn Urges Shareholders to
2y agoLAB SLGCSomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioToolsGlobeNewswireCombination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn's Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a
2y agoLAB OLK SLGC TMOMadryn Asset Management Issues Letter to Shareholders Correcting False and Misleading Statements in SomaLogic's Recent Investor PresentationBusiness WireHighlights Public Opposition to Proposed Merger from Skye Fund III, a Long-Term SomaLogic Investor Deeply Troubled by Information in Complaint Filed by Company Founder and Chief Technology Officer That Strongly
2y agoLAB SLGCSkye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioToolsGlobeNewswireBelieves that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet Iterates that SomaLogic can Thrive as a Standalone Enterprise
2y agoLAB OLK SLGCMadryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote "AGAINST" the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioToolsBusiness WireEncourages SomaLogic Shareholders to Visit www.NoSomaLogicMerger.com to View Presentation and Learn How to Vote "AGAINST" the Proposed Merger Madryn Plans to Send a GREEN Proxy Card to SomaLogic Shareholders, and
2y agoSLGCSLGC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Merger of SomaLogic With Standard BioToolsGlobeNewswireMONSEY, N.Y., Dec. 13, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed merger of SomaLogic, Inc. (NASDAQ:SLGC) ("SomaLogic") with Standard BioTools Inc. in
2y agoEXAS ILMN LAB ME+4Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioToolsBusiness WireFiles Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and
2y agoLAB SLGCLowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC)GlobeNewswireNEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc.
2y agoLAB SLGCLowey Dannenberg, P.C. is Investigating Proposed Merger Between Standard BioTools Inc. (NASDAQ: LAB) and SomaLogic, Inc. (NASDAQ: SLGC)GlobeNewswireNEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc.
2y agoLAB SLGCStandard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed MergerGlobeNewswireSOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and
3y agoSLGCSomaLogic Inc. (SLGC) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoSLGCSomaLogic Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsGlobeNewswireRevenue of $22.0 million, reflecting 14% year-over-year growth when excluding royalty revenue from NEB in the corresponding prior-year periodCash and investments of over $450 millionRaising full year 2023 revenue
3y agoSLGCSomaLogic announces new SomaScan® 11K PlatformGlobeNewswireBOULDER, Colo., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (NASDAQ:SLGC), a leader in data-driven proteomics technology, today announced the launch of its high-plex proteomics platform, which provides 11,000
3y agoSLGCSomaLogic to Announce Third Quarter 2023 Financial Results on November 8, 2023GlobeNewswireBOULDER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the third quarter 2023 after market close on November 8,
3y agoSLGCOncoHost to Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients at SITC 2023PR NewswireOncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, has developed a novel computational...
3y agoSLGCJournal of Pharmaceutical & Biomedical Analysis Publishes Study Analytically Validating OncoHost's PROphet® Test as a Decision Support Tool for Metastatic NSCLC PatientsPR NewswireOncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a peer-reviewed article ...
3y agoSLGCBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LiveVox Holdings, Inc. (Nasdaq - LVOX), Standard BioTools Inc. (Nasdaq - LAB), PFSweb, Inc. (Nasdaq – PFSW), Hostess Brands, Inc. (Nasdaq – TWNK)GlobeNewswireBALA CYNWYD, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
3y agoLAB SLGCStandard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences ToolsGlobeNewswireActivates Standard BioTools' strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power
3y agoSLGCOncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung CancerPR NewswireProteomic Pattern Recognition Technology to Help Identify and Characterize Potential Resistance Patterns in Recruited Patients, Provide Correlative Biomarkers to Guide Outcomes
3y agoSLGCSomaLogic and Korea's DNA Link partner to bring the 7,000-plex SomaScan® platform to the fast-growing Asia-Pacific proteomics marketGlobeNewswireBOULDER, Colo. and SEOUL, Korea, Sept. 19, 2023 (GLOBE NEWSWIRE) -- SomaLogic Inc., (NASDAQ:SLGC), a leader in data-driven proteomics technology, today announced its partnership with DNA Link, an innovator in
3y agoSLGCSomaLogic researchers identify key proteins to aid in early detection of lung, colon and breast cancer and ovarian tumorsGlobeNewswireBOULDER, Colo., Sept. 12, 2023 (GLOBE NEWSWIRE) -- In a new paper published in Nature's Scientific Reports, researchers at SomaLogic Inc. studied the value of protein biomarkers in the early detection of cancer and
3y agoSLGCSomaLogic expands agreement with Novo Nordisk to 2025GlobeNewswireBOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As
3y agoSLGCSomaLogic Reports Second Quarter 2023 Financial ResultsGlobeNewswireRevenue of $20.5 million, an increase of 45% year-over-yearCash and investments of approximately $474 million, a strong capital position to fund current and future business initiativesReiterating full year 2023 revenue
3y agoSLGCSomaLogic to Announce Second Quarter 2023 Financial Results on August 14, 2023GlobeNewswireBOULDER, Colo., July 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the second quarter 2023 after market close on August 14th,
3y agoSLGCSomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in EuropeGlobeNewswireBOULDER, Colo. and L'AQUILA, Italy, July 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic Operating Co. Inc., (NASDAQ:SLGC), a leader in data-driven proteomics technology, today announced its partnership with Dante Genomics, a
3y agoSLGCSomaLogic partners with Dante Genomics to enhance clinical and research adoption of proteomics in EuropePR NewswireSomaLogic's 7,000-plex SomaScan® Platform will be used in proteomics testing at scale in Europe. BOULDER, Colo. and L'AQUILA, Italy, July 24, 2023 /PRNewswire/ -- SomaLogic Operating Co. Inc., (NASDAQ:SLGC),
3y agoSLGCSomaLogic Partners with Citogen to Expand Authorized Site Program in EuropeGlobeNewswireBOULDER, Colo., June 12, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today their collaboration with Citogen, the Longwood Group's customer services and support unit, to
3y agoSLGCSomaLogic Announces Chief Financial Officer TransitionGlobeNewswireAppoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics
3y agoSLGCSomaLogic to Participate in the Jefferies Healthcare ConferenceGlobeNewswireBOULDER, Colo., May 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming Jefferies Healthcare Conference. SomaLogic
3y agoSLGCSomaLogic Reports First Quarter 2023 Financial ResultsGlobeNewswireFirst quarter 2023 revenue of $20.4 million, representing a decrease of 11% year-over-year; excluding licensing, revenue increased 2% year-over-yearReiterating full year 2023 revenue guidance of $80-84 million Expense
3y agoSLGCSomaLogic expands into China with groundbreaking Biostar Technology Limited PartnershipGlobeNewswireSHANGHAI and BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Biostar Technology Limited will be the company's first authorized site in China to
3y agoSLGCSomaLogic opens their first-ever proteomics grant program to APAC life sciences researchersGlobeNewswireTwo winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan® Platform at Genomax's Singapore lab SINGAPORE & BOULDER, Colo., May 07, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc.,